MedTrace Logo

Role of Low-Molecular-Weight Heparin in Unexplained Recurrent Pregnancy Loss

NCT06484634 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 175

Last updated 2024-07-03

No results posted yet for this study

Summary

Using low-molecular-weight heparin (LMWH), outcomes such as live birth rate and the occurrence of pregnancy complications are some of the variables reported in some studies, with varying degrees of success. The present study aimed to compare the role of LMWH in unexplained recurrent pregnancy loss.

Conditions

  • Pregnancy Loss

Interventions

DRUG

Low molecular weight heparin

A daily dose of 40 mg of low-molecular-weight heparin (LMWH) subcutaneously was given to the patients.

Sponsors & Collaborators

  • RESnTEC, Institute of Research

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
44 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2024-05-31
Completion
2024-05-31

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06484634 on ClinicalTrials.gov